Skip to main
NRIX
NRIX logo

NRIX Stock Forecast & Price Target

NRIX Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Nurix Therapeutics Inc. is poised for significant growth due to its innovative pipeline, particularly with NX-5948, which has shown clinical activity and improvements in overall response rates for heavily pre-treated chronic lymphocytic leukemia (CLL) patients. The company's strategic collaborations with partners like Gilead Sciences (GILD) and its ability to navigate the complexities of protein modulation uniquely position it in the biopharmaceutical landscape, suggesting a competitive advantage that could lead to considerable peak sales potential. Additionally, while research and development expenses are anticipated to rise as Nurix prepares for pivotal studies, this investment underscores the company's commitment to advancing its promising therapies, indicating a strong long-term outlook.

Bears say

Nurix Therapeutics Inc. is facing significant financial challenges, highlighted by a GAAP net loss of $59 million, or $(0.75) per share, which exceeded prior estimates and indicates increasing R&D-related expenses. Additionally, the company anticipates potential setbacks in its pipeline, including negative clinical outcomes and delays in obtaining regulatory approvals for key drug candidates like NX-2127 and NX-5948, which could adversely affect market uptake and investor sentiment. Furthermore, concerns about dilution risks and the company's ability to develop successful clinical candidates using its DELigase platform contribute to a negative outlook for Nurix's stock performance.

NRIX has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nurix Therapeutics, Inc (NRIX) Forecast

Analysts have given NRIX a Buy based on their latest research and market trends.

According to 19 analysts, NRIX has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nurix Therapeutics, Inc (NRIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.